The Efficacy and Safety of Acupoint Stimulation for Fetal Malpresentation/Malposition During Pregnancy, Labor, or Birth: A Scoping Review

Author(s):  
Heidi Williams ◽  
Dianne Bloxsome ◽  
Sara Bayes ◽  
Carol chungfeng Wang
Author(s):  
Pedro Jesús Gómez-Arias ◽  
Francisco Gómez-García ◽  
Jorge Hernández-Parada ◽  
Ana María Montilla-López ◽  
Juan Ruano ◽  
...  

2018 ◽  
Vol 8 (2) ◽  
pp. 195-202 ◽  
Author(s):  
Francisco Gómez-García ◽  
Juan Ruano ◽  
Jesús Gay-Mimbrera ◽  
Macarena Aguilar-Luque ◽  
Juan L. Sanz-Cabanillas ◽  
...  

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  

Abstract Background: High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the efficacy and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design: This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored. Discussion: This trial will explore the feasibility and provide potential evidence for the efficacy and safety of TEAS plus lifestyle modification for high-normal BP. The results of this study will be published in a peer-reviewed journal. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900024982. Registered on August 6, 2019.


2015 ◽  
Vol 29 (4) ◽  
pp. 12-22
Author(s):  
Ho yeol Cha ◽  
A Ram Jung ◽  
Jin Hong Cheon ◽  
Jun Yong Choi ◽  
Ki Bong Kim

Heart ◽  
2021 ◽  
pp. heartjnl-2021-319643
Author(s):  
Arushi Singh ◽  
Anubha Agarwal ◽  
Q. Eileen Wafford ◽  
Sanjiv J Shah ◽  
Mark Huffman ◽  
...  

ObjectiveDiuretics reduce congestion in patients with heart failure with preserved ejection fraction (HFpEF). However, comparison of clinical effects across diuretic classes or combinations of diuretics in patients with HFpEF are not well described. Therefore, we sought to conduct a scoping review to map trial data of diuretic efficacy and safety in patients with HFpEF.Review methods and resultsWe searched multiple bibliometric databases for published literature and ClinicalTrials.gov, and hand searched unpublished studies comparing different classes of diuretics to usual care or placebo in patients with HFpEF. We included randomised controlled trials or quasi-experimental studies. Two authors independently screened and extracted key data using a structured form. We identified 13 published studies on diuretics in HFpEF, with 1 evaluating thiazide use, 7 on mineralocorticoid receptor antagonists (MRAs) and 5 on sodium-glucose co-transporter 2 inhibitors (SGLT2i). There remain 17 ongoing trials evaluating loop diuretics (n=1), MRAs (n=5), SGLT2i (n=10) and a polydiuretic (n=1), including 2 well-powered trials of SGLT2i that will be completed in 2021.ConclusionsThe limited number of published trials evaluating different classes of diuretics in patients with HFpEF have been generally small and short term. Ongoing and emerging trials of single or combination diuretics with greater power will be useful to better define their safety and efficacy.Scoping review registrationdoi:10.18131/g3-dejv-tm77.


2021 ◽  
pp. 030089162098593
Author(s):  
Dmitriy Viderman ◽  
Antonio Sarria-Santamera

Chronic pain is reaching epidemic levels. Chronic pain represents a significant burden for patients, healthcare systems, and society, given its impact on quality of life, increased disability, and risk of hospitalization and mortality. Unmet needs of chronic pain management are also significant as only a small percentage of patients respond to medical (drug) therapy. Erector spinae plane block (ESPB) was rapidly adapted in clinical practice and numerous cases have been published assessing its effectiveness, but no systematic review of evidence on ESPB in chronic pain management is available. The purpose of this scoping review is to perform a comprehensive overview of existing evidence on ESPB in chronic pain management. We analyzed cases and case series reporting 43 patients. ESPB was performed in patients with severe pain and in all cases resulted in some degree of pain relief. However, because there was heterogeneity in mechanisms and underlying causes of chronic pain, preprocedural analgesic therapy, and pain assessment in reporting the cases, with the information currently available (case reports) we cannot make a definitive conclusion regarding efficacy and safety of ESPB in chronic pain management. Lack of homogeneity was present in medication use before the procedure, indicating a significant variation in how patients with chronic pain are managed. Variation in clinical practice can indicate the need to improve the quality of care to alleviate the chronic pain burden. Randomized controlled clinical trials are warranted to establish efficacy and safety of ESPB in chronic pain management.


Medicine ◽  
2021 ◽  
Vol 100 (25) ◽  
pp. e26348
Author(s):  
Dan Meng ◽  
Yifei Mao ◽  
Quanmei Song ◽  
Chunchun Yan ◽  
Qinyu Zhao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document